Cipla Limited-Fundamental and Technical Analysis
Founder: Khwaja Abdul Hamied
CEO: Umang Vohara
Founded: 1935
Large Cap Company, market cap: 61,374 (Cr)
Fundamental Overview
Profit making company, it is in increasing order from last 5 years.
Company is expected to give good quarterly result.
| Quarterly | JUN 2020 | MAR 2020 | DEC 2019 | SEP 2019 | JUN 2019 |
| Sales | 4,346.16 | 4,376.19 | 4,371.00 | 4,395.78 | 3,989.02 |
| Other Income | 65.45 | 93.18 | 72.13 | 100.52 | 78.37 |
| Total Income | 4,411.61 | 4,469.37 | 4,443.13 | 4,496.30 | 4,067.39 |
| Net Profit | 571.43 | 242.31 | 353.58 | 480.44 | 470.65 |
Trending
This is the main reason to increasing in sales quarter by quarter cipla has launched Favipiravir drug in India for treatment of COVID-19 patients. It will be commercially launched under the brand name Ciplenza at the rate of Rs. 68 per tablet, it is cheapest tablet as compare to other brands.
Technical Analysis:
Price has given positive breakout on monthly candle, this chart expecting positive movement in long -term. Breakout point is 753 buy above 760 and keep stop loss on 680, for the target 910 for medium-term and long-term.
Chart Analysis
2,353 total views, 1 views today
